What is claimed is:

1. A compound having the structure:



wherein

one of R_1 or R_2 is $-C(=O)OH$ and the other of R_1 or R_2 is $-C(=O)OR_{13}$ or $-C(=O)O-alkyl-R_{14}$,

wherein

R_{13} is aryl, and

R_{14} is aryl, and

R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each independently, $-H$, $-OR_{15}$ or halogen,

wherein R_{15} is C_{1-10} alkyl,

wherein when one of R_1 or R_2 is $-C(=O)OH$ and R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each H, then the other of R_1 or R_2 is other than $-C(=O)OR_{13}$ where R_{13} is 1-naphthyl or 2-naphthyl, or $-C(=O)O-alkyl-R_{14}$ where the alkyl is a branched C_2 alkyl and the R_{14} is phenyl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein when one of R_1 or R_2 is $-C(=O)OH$ and R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each H, then the other of R_1 or R_2 is other than $-C(=O)OR_{13}$ where R_{13} is tolyl, 1-naphthyl or 2-

naphthyl, or $-C(=O)O-alkyl-R_{14}$ where the alkyl is a branched C_2 alkyl and the R_{14} is phenyl.

3. The compound of claim 1, wherein when one of R_1 or R_2 is $-C(=O)OH$ and the other of R_1 or R_2 is $-C(=O)OR_{13}$ where R_{13} is 1-naphthyl or 2-naphthyl, then one of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} is other than $-H$; or

wherein when one of R_1 or R_2 is $-C(=O)OH$ and the other of R_1 or R_2 is $-C(=O)OR_{13}$ where R_{13} is 1-naphthyl or 2-naphthyl, then two of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than $-H$; or

wherein when one of R_1 or R_2 is $-C(=O)OH$ and the other of R_1 or R_2 is $-C(=O)OR_{13}$ where R_{13} is 1-naphthyl or 2-naphthyl, then four of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than $-H$.

4. The compound of claim 1,

wherein one of R_1 or R_2 is $-C(=O)OR_{13}$,

wherein R_{13} is aryl; and

the other of R_1 or R_2 is $-C(=O)OH$.

5. The compound of claim 1,

wherein one of R_1 or R_2 is $-C(=O)O-alkyl-R_{14}$,

wherein R_{14} is aryl; and

the other of R_1 or R_2 is $-C(=O)OH$.

6. The compound of claim 4, wherein the aryl is a substituted aryl, wherein the aryl is substituted with a halogen, heteroaryl, C_2-C_6 alkynyl, -O(alkyl), amide, aryl or hydroxyaryl.

7. The compound of claim 6, wherein the aryl is substituted with a F, Cl, Br, I, $-NHC(O)CH_3$, triazolyl, C_2 alkynyl, phenyl, *o*-hydroxyphenyl or $-OCH_3$.

8. A compound having the structure:



,

wherein R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each independently, H, $-OR_{15}$ or halogen,

wherein R_{15} is C_{1-10} alkyl,

wherein when one of R_1 or R_2 is $-C(=O)OH$ and R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each H, then the other of R_1 or R_2 is other than $-C(=O)OR_{13}$ where R_{13} is 1-naphthyl or 2-naphthyl, or $-C(=O)O-alkyl-R_{14}$ where the alkyl is a branched C_2 alkyl and the R_{14} is phenyl, and

wherein one of R_1 or R_2 is



,



,



,



,



or



, and

the other of R_1 or R_2 is $-C(=O)OH$; or

wherein

one of R_1 or R_2 is

, , ,

,  or , and

the other of R_1 or R_2 is –C(=O)OH; or

wherein

one of R_1 or R_2 is

, , ,

, , or ; and

the other of R_1 or R_2 is –C(=O)OH,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, wherein R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are each independently, –H, halogen or $-OR_{15}$,

wherein R_{15} is C_{1-6} alkyl.

10. The compound of claim 1, wherein two of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H; or wherein four of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H.

11. The compound of claim 1, wherein R_3, R_4, R_6, R_7, R_8, R_9, R_{11} and R_{12} are each –H; and R_5 and R_{10} are each halogen or $-OR_{15}$,

wherein R_{15} is C_{1-10} alkyl; or

wherein R_4, R_5, R_6, R_9, R_{10} and R_{11} are each –H; R_3 and R_{12} are each –H, halogen or $-OR_{15}$; and R_7 and R_8 are each halogen or $-OR_{15}$,

wherein R_{15} is C_{1-10} alkyl; or

wherein R_3, R_4, R_7, R_8, R_9 and R_{12} are each –H; and R_5, R_6, R_{10} and R_{11} are each halogen or $-OR_{15}$,

wherein R_{15} is C_{1-10} alkyl.

12. The compound of claim 1, wherein the compound is the (S,S) enantiomer.

13. The compound of claim 1, wherein the compound is the (R,R) enantiomer.

14. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

15. The composition of claim 14, wherein the composition comprises a mixture of enantiomers enriched in (S,S) enantiomer or a mixture of enantiomers enriched in (R,R) enantiomer.

16. The compound of claim 1, wherein R_{13} is substituted phenyl, unsubstituted naphthyl or unsubstituted indanyl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1, wherein R_{13} is unsubstituted aryl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17,

wherein two of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H; or

wherein four of R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11} and R_{12} are other than –H.

19. A compound having the structure:



,


,


,



,



,



or



,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

20. A compound having the structure:


OMe
COOH
OMe,
O
O

,


OMe
COOH
OMe,
O
O

or


Cl
COOH
Cl
O
O

,


OH
HO
O
O
O
HO

, or


OH
OMe
HO
O
O
MeO
HO

,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

21. A compound having the structure:



,



,



,



,



,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.